TY  - BOOK
AU  - Baez-Sosa, Valentina
AU  - Chaturvedi, Mansi
AU  - Desai, Sanjal
AU  - Hameed, Rumaisa
AU  - Shenoy, Aarthi G
TI  - Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma
SN  - 1083-7159
PY  - 2021///
KW  - *Antineoplastic Combined Chemotherapy Protocols
KW  - *Lymphoma, Large B-Cell, Diffuse
KW  - Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - Cyclophosphamide/tu [Therapeutic Use]
KW  - Doxorubicin/tu [Therapeutic Use]
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse/dt [Drug Therapy]
KW  - Prednisone/tu [Therapeutic Use]
KW  - Prognosis
KW  - Retrospective Studies
KW  - Rituximab/tu [Therapeutic Use]
KW  - Vincristine/tu [Therapeutic Use]
KW  - MedStar Washington Hospital Center
KW  - Washington Cancer Institute
KW  - Hematology/Oncology Fellowship
KW  - Internal Medicine Residency
KW  - Journal Article
N1  - Available online from MWHC library: 1996 - present
N2  - Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single-center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose-adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA-EPOCH-R) comparative with de novo DLBCL. Of 170 patients with DLBCL, 136 were de novo, 17 were concurrent, and 17 were transformed. Transformed DLBCL had significantly lower complete response rates and progression-free survival (PFS) but similar overall survival (OS) compared with de novo counterpart. There was no significant difference between de novo and concurrent DLBCL regarding response rates, PFS, and OS. DA-EPOCH-R was associated with inferior OS. Thus, intensified treatment with DA-EPOCH-R might not improve outcomes of transformed DLBCL. Copyright (c) 2021 AlphaMed Press
UR  - https://dx.doi.org/10.1002/onco.13846
ER  -